Abstract
Background The MET tyrosine kinase and its ligand, hepatocyte growth factor (HGF) also known as scatter factor, are associated with tumourigenesis and metastasis by promotion of scattering, proliferation, angiogenesis, motility and invasion. ASLAN-002 is a potent inhibitor of MET as well as related kinases. A phase I dose escalation study was conducted to determine the safety and pharmacokinetics of ASLAN-002 in patients with advanced cancer. Methods Patients with advanced or metastatic solid tumours, who had progressed on standard therapy or for whom standard therapy was not known, were administered ASLAN-002 orally. The starting dose was 100 mg once daily (QD) with subsequent cohorts to receive doses of 200 mg QD, 300 mg QD, 450 mg QD, 600 mg QD, 300 mg twice daily (BID), 450 mg BID, and 600 mg BID. Results Forty patients were included across 7 dose cohorts. Cohort 8 (600 mg BID) was not opened due to the lack of appreciable pharmacokinetic (PK) differences between 300 mg BID and 450 mg BID and higher incidences of grade 3 or 4 adverse events (AE) in Cohort 7 (450 mg BID). Fifteen patients (37.5%) experienced a grade 3 or 4 AE. The most commonly reported AEs were nausea (55%), fatigue (47.5%) and constipation (30%). One dose ...Continue Reading
References
Apr 22, 1994·Cell·C PonzettoP M Comoglio
Dec 26, 2001·Cytokine & Growth Factor Reviews·Gautam MaulikRavi Salgia
Jun 1, 2005·Cancer Letters·James G ChristensenRavi Salgia
Jul 4, 2007·Journal of Cellular Physiology·Silvia Benvenuti, Paolo M Comoglio
Mar 6, 2009·Journal of Medicinal Chemistry·Gretchen M SchroederRobert M Borzilleri
Dec 1, 2011·Therapeutic Advances in Medical Oncology·J Rafael Sierra, Ming-Sound Tsao
May 2, 2012·Investigational New Drugs·Jeffrey R InfanteRamesh K Ramanathan
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George R BlumenscheinAna M Gonzalez-Angulo
Nov 22, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David C SmithMaha Hussain
Dec 11, 2013·Journal of Medicinal Chemistry·J Jean Cui
Dec 12, 2013·Oncoimmunology·Henok EyobAlana L Welm
Jan 5, 2014·Pharmacology & Therapeutics·Christiane R Maroun, Tracey Rowlands
Jun 27, 2014·The Lancet Oncology·Timothy IvesonElwyn Loh
Oct 4, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·L Rhoda MolifeMalcolm Richard Ranson
Dec 4, 2014·The New England Journal of Medicine·Benjamin J SolomonUNKNOWN PROFILE 1014 Investigators
Mar 7, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martijn P LolkemaFerry A L M Eskens
Apr 25, 2015·Journal of Clinical Pharmacology·Linh NguyenSteven Lacy
Jul 15, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio ScagliottiBrian Schwartz
Sep 26, 2015·The New England Journal of Medicine·Toni K ChoueiriUNKNOWN METEOR Investigators
Jul 13, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew SmithKarim Fizazi
Jul 28, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Tony Shu Kam MokKeunchil Park
Dec 13, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R SpigelTony Mok
Oct 21, 2014·Biomedicines·Simona GalloTiziana Crepaldi
Citations
Jun 4, 2020·Micromachines·Chaithanya ChelakkotYoung Kee Shin
Dec 1, 2019·Expert Opinion on Investigational Drugs·Helena OliveresJoan Maurel
May 16, 2019·Molecular Cancer·Kayla V MyersKenneth J Pienta
Dec 2, 2020·British Journal of Cancer·Derek DustinSuzanne A W Fuqua
Feb 11, 2021·Pharmaceuticals·Chao-Ju Chen, Yu-Peng Liu
Jan 20, 2021·Clinical and Translational Medicine·Neng WangZhiyu Wang
Jun 20, 2021·Oncogene·Jianjiang FuJuan Peng
Aug 1, 2021·Cancer Discovery·Shu-Chin Alicia LaiAlana L Welm